Ben Shin
Pain Medicine · New York, NYNPI 1245616044
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $17,196 with a category attached, or 87.2%. Boston Scientific accounts for 89.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $15,161 and has fallen 98.1% since, to $285 in 2025. Among pain medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $390.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Medtronic$682
- Abbott$570
- MML US, Inc.$248
- SPR Therapeutics, Inc$225
- Nevro Corp.$149
- plus $22 from 1 others
What the payments were for
- Grants$15,00087%
- Travel & lodging$250%
- Food & beverage$2,09612%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $15,300 |
| Medtronic(2 entities) | 16 | $682 |
| Abbott | 11 | $570 |
| MML US, Inc. | 2 | $248 |
| SPR Therapeutics, Inc | 5 | $225 |
| Nevro Corp. | 4 | $149 |
| Biogen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$15,000
- Proclaim Family of SCS IPGs$276
- ReActiv8$248
- GENERAL PAIN MANAGEMENT$139
- INTELLIS ADAPTIVESTIM$136
- SUPERION$113
- SPRINT PNS System$109
How this compares
$17,196 in reported general payments places this provider in the 90th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 158 | $1,210 |
| Baclofen | 143 | $1,174 |
| Meloxicam | 87 | $136 |
| Methylprednisolone | 17 | $102 |
| Pregabalin | 15 | $84 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in New York
- Amitabh GulatiNew York$614K
- David SpinnerNew York$391K
- Eric LeeNew York$117K
- Christopher GhariboNew York$91K
- Randa JaafarNew York$87K
- Boris LeybelNew York$58K
- Chirag ShahNew York$48K
- Annie Layno-MosesNew York$29K
- Raj MurthyNew York$24K
- David CassagnolNew York$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.